Bulk Pharmaceutical API Sources for ELCYS

Bulk Pharmaceutical API Sources for ELCYS

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C121800_ALDRICH
Sigma-Aldrich		C6852_SIAL
Sigma-Aldrich		C7880_SIAL
NovoSeek		23462
Sigma-Aldrich		30129_SIGMA
ISpharm		I14-2743
MolPort		MolPort-003-929-587

Bulk Active Pharmaceutical Ingredient (API) Sources for ELCYS

Last updated: February 19, 2026

ELCYS is a fixed-dose combination product containing empagliflozin and linagliptin. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for glycemic control in type 2 diabetes. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor also used for glycemic control in type 2 diabetes. The development and sourcing of bulk Active Pharmaceutical Ingredients (APIs) for such combination therapies are critical for market entry and supply chain stability.

What are the primary bulk API sourcing considerations for ELCYS?

Sourcing bulk APIs for ELCYS involves a multi-faceted approach. Key considerations include the availability and quality of both empagliflozin and linagliptin APIs, the regulatory compliance of potential suppliers, cost-effectiveness, and the security of the supply chain. Dual sourcing strategies are often employed to mitigate risks associated with single-supplier dependence.

Empagliflozin API Sourcing

Empagliflozin's synthesis is a complex multi-step process. Manufacturers require access to specialized intermediates and stringent process controls to ensure API purity and consistency. Global API manufacturers specializing in complex organic synthesis are primary targets.

Key Characteristics of Empagliflozin API

• Chemical Name: 1-chloro-4-(β-D-glucopyranos-1-yl)-6-[4-({3-[4-(4-fluorophenyl)piperidin-1-yl]propyl}amino)phenyl]benzene
• Molecular Formula: C₂₃H₂₅ClO₆S
• Molecular Weight: 452.96 g/mol
• Therapeutic Class: SGLT2 Inhibitor
• Regulatory Status: Approved by major regulatory bodies including FDA, EMA, and others.

Potential Empagliflozin API Manufacturers

Several API manufacturers globally produce empagliflozin. Due diligence on each potential supplier is essential, focusing on their manufacturing capabilities, adherence to Good Manufacturing Practices (GMP), and regulatory inspection history.

• Boehringer Ingelheim: As the originator of empagliflozin (Jardiance®), Boehringer Ingelheim likely has significant internal API manufacturing capacity or closely controlled contract manufacturing organizations (CMOs).
• Generic API Manufacturers: A number of global API players, particularly in India and China, are developing or manufacturing generic empagliflozin API. Examples include:
  • Divi's Laboratories: Known for complex API synthesis and regulatory expertise.
  • Laurus Labs: A significant player in complex API development and manufacturing.
  • Dr. Reddy's Laboratories: Possesses broad API manufacturing capabilities and a strong regulatory track record.
  • Aarti Industries: Has expertise in specialty chemicals and intermediates, which can be leveraged for API synthesis.

The selection process typically involves:

1. Quality Audits: On-site inspections of manufacturing facilities to verify GMP compliance.
2. Regulatory Dossier Review: Assessment of Drug Master Files (DMFs) or Certificates of Suitability (CEPs) submitted to regulatory authorities.
3. Technical Capability Assessment: Evaluation of the manufacturer's process chemistry, analytical capabilities, and capacity.
4. Supply Chain Robustness: Assessment of raw material sourcing, inventory management, and business continuity plans.

Linagliptin API Sourcing

Linagliptin is also a complex molecule requiring specialized synthesis. Its production involves multiple chemical steps, and ensuring stereochemical purity is paramount.

Key Characteristics of Linagliptin API

• Chemical Name: 8-[(3R)-3-aminopiperidin-1-yl]-7-(4-butan-2-yl-phenyl)-3-methyl-2,4(1H,3H)-quinazolinedione
• Molecular Formula: C₂₅H₃₀N₄O₂
• Molecular Weight: 402.53 g/mol
• Therapeutic Class: DPP-4 Inhibitor
• Regulatory Status: Approved by major regulatory bodies including FDA, EMA, and others.

Potential Linagliptin API Manufacturers

Similar to empagliflozin, linagliptin is manufactured by originator companies and a growing number of generic API producers.

• Boehringer Ingelheim: Originator of linagliptin (Tradjenta®/Trajenta®).
• Generic API Manufacturers:
  • Aurobindo Pharma: A prominent supplier of APIs with a strong focus on regulated markets.
  • Hetero Drugs: Known for its API manufacturing prowess and extensive product portfolio.
  • Granules India: Offers a wide range of APIs, including those for chronic disease management.
  • Industrias Químicas del Valles (IQV): A Spanish API manufacturer with a focus on complex molecules.

The evaluation criteria for linagliptin API suppliers mirror those for empagliflozin, emphasizing GMP compliance, regulatory filings, technical expertise, and supply chain resilience.

What are the regulatory requirements for API sourcing for ELCYS?

Sourcing APIs for a combination product like ELCYS is subject to stringent regulatory oversight by health authorities worldwide. These regulations aim to ensure the quality, safety, and efficacy of the final drug product.

Good Manufacturing Practices (GMP)

All API manufacturers must adhere to cGMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). GMP compliance covers all aspects of production and quality control, including:

• Facility Design and Maintenance: Appropriate environmental controls, cleanroom classifications, and prevention of cross-contamination.
• Personnel Training and Hygiene: Qualified staff and strict hygiene protocols.
• Raw Material Control: Vendor qualification and testing of incoming materials.
• Process Validation: Documented evidence that manufacturing processes consistently produce APIs meeting predetermined specifications.
• Analytical Testing: Robust in-process and final product testing using validated methods.
• Record Keeping: Comprehensive documentation of all manufacturing and quality control activities.
• Change Control and Deviation Management: Formal systems for managing changes and investigating deviations.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

API manufacturers typically submit a DMF to regulatory agencies like the FDA. The DMF contains detailed information about the API's manufacturing process, facility, quality control, and stability. Pharmaceutical companies manufacturing the finished drug product can then reference the DMF in their marketing applications.

Similarly, in Europe, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is often required. A CEP certifies that the quality of an API is suitably controlled by the monograph(s) of the European Pharmacopoeia.

For a combination product like ELCYS, separate DMFs or CEPs are required for both empagliflozin and linagliptin APIs.

Stability Studies

API manufacturers must conduct comprehensive stability studies to establish the retest period or shelf life of the API. These studies are performed under various storage conditions (e.g., long-term, intermediate, accelerated) to assess degradation pathways and ensure the API remains within specification throughout its intended storage period.

Impurity Profiling and Control

A critical aspect of API sourcing is the control of impurities. This includes:

• Process-Related Impurities: Byproducts formed during synthesis.
• Degradation Products: Resulting from storage or handling.
• Residual Solvents: Solvents used in manufacturing that remain in the API.
• Genotoxic Impurities (GTIs): Impurities with the potential to damage DNA, requiring particularly stringent control limits.

ICH guidelines (e.g., ICH Q3A, ICH Q3C, ICH M7) provide frameworks for the identification, qualification, and control of impurities.

Supply Chain Security and Traceability

Pharmaceutical companies are increasingly focused on securing their supply chains against counterfeiting and ensuring the traceability of APIs from their origin to the finished drug product. This involves:

• Supplier Qualification Programs: Rigorous vetting of all suppliers.
• Audit Trails: Comprehensive logs of all transactions and movements.
• Serialization: Implementing serialization at the API batch level where feasible.
• Background Checks: For key personnel involved in logistics.

How does the regulatory landscape impact API sourcing costs for ELCYS?

The rigorous regulatory framework for API sourcing has a direct impact on the cost of both empagliflozin and linagliptin. Compliance with GMP, conducting extensive validation studies, and maintaining detailed documentation require significant investment by API manufacturers.

Cost Drivers

• GMP Compliance: Implementing and maintaining cGMP standards is expensive, involving capital investments in facilities and equipment, ongoing training, and robust quality management systems.
• Process Development and Validation: Developing and validating complex synthetic routes for empagliflozin and linagliptin requires substantial R&D expenditure. Process validation alone can cost hundreds of thousands of dollars per API.
• Analytical Method Development and Validation: Developing and validating analytical methods for release testing and impurity profiling is time-consuming and costly.
• Stability Studies: Conducting ICH-compliant stability studies for the API's shelf life is a long-term financial commitment.
• Regulatory Filings: Preparing and submitting DMFs or CEPs and responding to queries from regulatory authorities incurs significant administrative and expert costs.
• Quality Control and Assurance: Maintaining a dedicated QA/QC department with qualified personnel and advanced analytical instrumentation adds to operational expenses.
• Environmental, Health, and Safety (EHS) Compliance: Adhering to strict EHS regulations for chemical manufacturing processes can increase operational costs.

Cost Comparisons

Generally, APIs manufactured in highly regulated markets (e.g., Europe, North America) tend to have higher costs due to the stringency of local regulations and higher labor costs. However, APIs from manufacturers in India and China, while often more cost-competitive, must still demonstrate equivalent GMP compliance and regulatory adherence to be accepted by major pharmaceutical companies.

For ELCYS, the cost of sourcing empagliflozin API can range from $200 to $800 per kilogram, depending on the supplier, volume, and regulatory filings. Linagliptin API costs can similarly range from $300 to $1,200 per kilogram. These are estimates and can fluctuate based on market dynamics, raw material prices, and patent exclusivity periods. The combination of two APIs, each with its own complex synthesis and regulatory pathway, contributes to the overall API sourcing cost for ELCYS.

What are the intellectual property considerations for ELCYS API sourcing?

The intellectual property (IP) landscape surrounding empagliflozin and linagliptin is a critical factor in API sourcing, particularly for generic manufacturers or companies developing combination products that may compete with originator therapies.

Patent Exclusivity

• Empagliflozin: The primary patents protecting empagliflozin are held by Boehringer Ingelheim. These patents cover the compound itself, its synthesis, and its therapeutic uses. Key patents related to empagliflozin are expected to expire in the US around 2028-2030 and in Europe within a similar timeframe, though specific expiry dates can vary by jurisdiction and secondary patents.
• Linagliptin: Similarly, linagliptin is patented by Boehringer Ingelheim. Its compound patents are also anticipated to expire around the late 2020s in major markets.

Impact on Generic API Sourcing

For companies intending to produce generic versions of ELCYS or a bioequivalent combination product, the expiry of these core compound patents is a prerequisite for market entry. API manufacturers must ensure their synthesis routes do not infringe on any existing process patents.

Potential IP Risks

• Process Patents: Even after compound patent expiry, manufacturers must be vigilant about existing process patents. Boehringer Ingelheim may have patents covering specific manufacturing methods for empagliflozin and linagliptin that offer efficiency or purity advantages.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can be patented, and using a patented polymorph without a license can lead to infringement.
• Formulation Patents: Patents may also cover specific formulations or methods of co-administration.

API sourcing for ELCYS, especially by generic manufacturers, requires thorough freedom-to-operate (FTO) analysis. This involves a comprehensive review of all relevant patents to ensure that the chosen API manufacturing process and the final drug product formulation do not infringe on any third-party IP rights. The timing of API sourcing decisions is heavily influenced by patent expiry dates and the potential for litigation.

What are the supply chain risks and mitigation strategies for ELCYS API sourcing?

The global nature of API manufacturing exposes the supply chain for ELCYS to various risks. Proactive identification and mitigation of these risks are essential for ensuring uninterrupted supply.

Key Supply Chain Risks

• Geopolitical Instability: Many APIs are manufactured in regions susceptible to political unrest, trade disputes, or export restrictions. This can disrupt production or create delays.
• Natural Disasters: Earthquakes, floods, and pandemics (as evidenced by COVID-19) can halt manufacturing operations and disrupt logistics.
• Raw Material Shortages: The synthesis of empagliflozin and linagliptin relies on specific chemical intermediates and raw materials, the availability of which can be volatile. Disruptions in upstream supply chains can impact API production.
• Quality Failures: Batch failures due to manufacturing errors or contamination can lead to recalls, production halts, and significant reputational damage.
• Regulatory Changes: Evolving regulatory requirements in manufacturing countries or for imported APIs can necessitate costly process adjustments or impact import/export permissions.
• Cybersecurity Threats: Increasingly, manufacturing and supply chain operations are vulnerable to cyberattacks, which can compromise data integrity, disrupt operations, or lead to intellectual property theft.
• Logistics and Transportation: Delays in shipping, customs issues, and the specialized handling requirements for certain chemical compounds can impact timely delivery.

Mitigation Strategies

• Dual/Multiple Sourcing: Establishing relationships with at least two qualified API manufacturers for each API (empagliflozin and linagliptin) in different geographical locations significantly reduces reliance on a single source. This strategy provides redundancy in case of disruptions.
• Geographical Diversification: Sourcing APIs from manufacturers located in different countries or regions mitigates risks associated with localized geopolitical events or natural disasters.
• Inventory Management: Maintaining strategic safety stocks of critical APIs and key intermediates can buffer against short-term supply disruptions. This must be balanced against inventory carrying costs and API shelf life.
• Supplier Audits and Relationship Management: Conducting regular, thorough audits of all API suppliers to ensure ongoing compliance with GMP and quality standards. Building strong, collaborative relationships with suppliers fosters transparency and early detection of potential issues.
• Contractual Agreements: Negotiating robust supply agreements that clearly define quality standards, delivery timelines, pricing, and contingency plans for force majeure events.
• Supply Chain Transparency: Mapping the entire supply chain, including Tier 2 and Tier 3 suppliers, to understand dependencies and identify potential vulnerabilities.
• Business Continuity Planning: Developing and regularly testing comprehensive business continuity plans that outline procedures for responding to various types of disruptions.
• Technology Adoption: Implementing supply chain visibility technologies, such as blockchain or advanced tracking systems, to enhance traceability and real-time monitoring.

The selection of API manufacturers for ELCYS should prioritize those with strong business continuity plans and established track records of reliability and quality.

Key Takeaways

• Sourcing bulk APIs for ELCYS requires rigorous due diligence on manufacturers of empagliflozin and linagliptin, focusing on GMP compliance, regulatory filings (DMFs/CEPs), and supply chain robustness.
• Key API manufacturers include originator companies like Boehringer Ingelheim and a growing number of global generic API producers in India and China.
• Stringent regulatory requirements, including GMP, impurity control, and stability studies, significantly influence API sourcing costs.
• Intellectual property considerations, particularly patent expiry dates and freedom-to-operate analyses, are critical for API sourcing strategies, especially for generic market entry.
• Supply chain risks, such as geopolitical instability, raw material shortages, and quality failures, necessitate mitigation strategies including dual sourcing, geographical diversification, and robust contractual agreements.

Frequently Asked Questions

1. Can API manufacturers from any country supply APIs for ELCYS to regulated markets like the US and EU?

No. API manufacturers must demonstrate compliance with the specific GMP standards and regulatory requirements of the target market. This often involves successful inspections by agencies like the FDA or EMA and the submission of acceptable DMFs or CEPs.

2. How is the quality of bulk APIs for ELCYS verified?

Quality is verified through rigorous testing of incoming raw materials, in-process controls, and final API release testing. This includes analytical methods to confirm identity, purity (including impurity profiling), potency, and other critical quality attributes, all performed according to validated methods and pharmacopoeial standards where applicable.

3. What is the typical lead time for sourcing bulk APIs like empagliflozin and linagliptin?

Lead times can vary significantly but generally range from 3 to 9 months from order placement to delivery, depending on the manufacturer's capacity, the complexity of the API, and existing inventory levels. Custom synthesis or development projects can take significantly longer.

4. Are there specific pharmacopoeial monographs for empagliflozin and linagliptin APIs?

Yes, major pharmacopoeias, such as the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph. Eur.), often establish monographs for widely used APIs. These monographs define official tests, procedures, and acceptance criteria. Manufacturers must comply with these monographs or justify alternative standards.

5. What is the difference between sourcing API from the originator and a generic manufacturer?

Sourcing from the originator typically ensures supply of the exact API used in the innovator drug, often with extensive historical quality data. However, it is generally more expensive. Sourcing from generic manufacturers can offer cost advantages and supply chain diversification but requires thorough qualification to ensure equivalent quality and regulatory compliance.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website] (Specific URL would depend on the exact section, but generally under the "Drugs" or "Compliance" sections).

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website] (Specific URL would depend on the exact section, but generally under the "Human regulatory" or "Quality" sections).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website] (Specific guidelines like Q3A, Q3C, M7 are relevant).

[4] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Specific URL would depend on the section detailing DMFs).

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM Website].